Here are the S-1 registration statements from Anteris Technologies Global Corp. (AVR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow AVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVR filings page.
Anteris Technologies Global Corp. is registering 9,103,796 shares of common stock for resale by existing investors. The shares consist of 2,346,936 already-issued shares, 2,346,936 shares issuable upon exercise of common stock warrants, 2,079,962 shares underlying CHESS Depositary Interests (CDIs), and 2,329,962 shares issuable upon exercise of CDI warrants. These securities were issued in an October–November 2025 private placement. Anteris will not receive proceeds from stockholder resales but could receive up to approximately $40.4 million if all related warrants are exercised at $7.50 per share for common stock warrants and A$11.50 per CDI for CDI warrants. As of September 30, 2025, 36,062,370 shares of common stock were outstanding. Anteris is a development-stage structural heart company focused on its DurAVR® transcatheter heart valve and the global PARADIGM pivotal trial in severe aortic stenosis; prior audited financials include an explanatory paragraph about substantial doubt regarding its ability to continue as a going concern.